{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T05:31:05Z","timestamp":1794547865038,"version":"4.9.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["JP19K17569"],"award-info":[{"award-number":["JP19K17569"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Myocardial infarction is still a life-threatening disease, even though its prognosis has been improved through the development of percutaneous coronary intervention and pharmacotherapy. In addition, heart failure due to remodeling after myocardial infarction requires lifelong management. The aim of this study was to develop a novel treatment suppressing the myocardial damage done by myocardial infarction. We focused on inhibition of soluble epoxide hydrolase to prolong the activation of epoxyeicosatrienoic acids, which have vasodilatory and anti-inflammatory properties. We successfully made a new vaccine to inactivate soluble epoxide hydrolase, and we have evaluated the effect of the vaccine in a rat myocardial infarction model. In the vaccinated group, the ischemic area was significantly reduced, and cardiac function was significantly preserved. Vaccine treatment clearly increased microvessels in the border area and suppressed fibrosis secondary to myocardial infarction. This soluble epoxide hydrolase vaccine is a novel treatment for improving cardiac function following myocardial infarction.<\/jats:p>","DOI":"10.1038\/s41598-022-10641-x","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T09:03:47Z","timestamp":1651136627000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A novel soluble epoxide hydrolase vaccine protects murine cardiac muscle against myocardial infarction"],"prefix":"10.1038","volume":"12","author":[{"given":"Takahiro","family":"Kitsuka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Shiraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-ichi","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Nakagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Node","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,28]]},"reference":[{"key":"10641_CR1","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/s0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2012","unstructured":"Lozano, R. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet (Lond., Engl.) 380, 2095\u20132128. https:\/\/doi.org\/10.1016\/s0140-6736(12)61728-0 (2012).","journal-title":"Lancet (Lond., Engl.)"},{"key":"10641_CR2","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1136\/heartjnl-2014-307310","volume":"101","author":"IR D\u00e9gano","year":"2015","unstructured":"D\u00e9gano, I. R. et al. Twenty-five-year trends in myocardial infarction attack and mortality rates, and case-fatality, in six European populations. Heart (Br. Card. Soc.) 101, 1413\u20131421. https:\/\/doi.org\/10.1136\/heartjnl-2014-307310 (2015).","journal-title":"Heart (Br. Card. Soc.)"},{"issue":"Suppl","key":"10641_CR3","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1194\/jlr.R800038-JLR200","volume":"50","author":"AA Spector","year":"2009","unstructured":"Spector, A. A. Arachidonic acid cytochrome P450 epoxygenase pathway. J. Lipid Res. 50(Suppl), S52-56. https:\/\/doi.org\/10.1194\/jlr.R800038-JLR200 (2009).","journal-title":"J. Lipid Res."},{"key":"10641_CR4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.yjmcc.2014.05.016","volume":"74","author":"A Oni-Orisan","year":"2014","unstructured":"Oni-Orisan, A., Alsaleh, N., Lee, C. R. & Seubert, J. M. Epoxyeicosatrienoic acids and cardioprotection: The road to translation. J. Mol. Cell. Cardiol. 74, 199\u2013208. https:\/\/doi.org\/10.1016\/j.yjmcc.2014.05.016 (2014).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10641_CR5","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1126\/science.285.5431.1276","volume":"285","author":"K Node","year":"1999","unstructured":"Node, K. et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285, 1276\u20131279. https:\/\/doi.org\/10.1126\/science.285.5431.1276 (1999).","journal-title":"Science"},{"key":"10641_CR6","doi-asserted-by":"publisher","first-page":"H2838","DOI":"10.1152\/ajpheart.00186.2008","volume":"294","author":"GJ Gross","year":"2008","unstructured":"Gross, G. J. et al. Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart. Am. J. Physiol. Heart Circ. Physiol. 294, H2838-2844. https:\/\/doi.org\/10.1152\/ajpheart.00186.2008 (2008).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10641_CR7","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ijcard.2011.12.062","volume":"167","author":"AR Kompa","year":"2013","unstructured":"Kompa, A. R. et al. Soluble epoxide hydrolase inhibition exerts beneficial anti-remodeling actions post-myocardial infarction. Int. J. Cardiol. 167, 210\u2013219. https:\/\/doi.org\/10.1016\/j.ijcard.2011.12.062 (2013).","journal-title":"Int. J. Cardiol."},{"key":"10641_CR8","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1161\/01.Res.0000237390.92932.37","volume":"99","author":"JM Seubert","year":"2006","unstructured":"Seubert, J. M. et al. Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ. Res. 99, 442\u2013450. https:\/\/doi.org\/10.1161\/01.Res.0000237390.92932.37 (2006).","journal-title":"Circ. Res."},{"key":"10641_CR9","doi-asserted-by":"publisher","first-page":"18733","DOI":"10.1073\/pnas.0609158103","volume":"103","author":"D Xu","year":"2006","unstructured":"Xu, D. et al. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc. Natl. Acad. Sci. U.S.A. 103, 18733\u201318738. https:\/\/doi.org\/10.1073\/pnas.0609158103 (2006).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10641_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1755-5922.2010.00150.x","volume":"29","author":"H Qiu","year":"2011","unstructured":"Qiu, H. et al. Soluble epoxide hydrolase inhibitors and heart failure. Cardiovasc. Ther. 29, 99\u2013111. https:\/\/doi.org\/10.1111\/j.1755-5922.2010.00150.x (2011).","journal-title":"Cardiovasc. Ther."},{"key":"10641_CR11","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.chest.2016.10.058","volume":"151","author":"L Yang","year":"2017","unstructured":"Yang, L. et al. Mechanisms of vascular dysfunction in COPD and effects of a novel soluble epoxide hydrolase inhibitor in smokers. Chest 151, 555\u2013563. https:\/\/doi.org\/10.1016\/j.chest.2016.10.058 (2017).","journal-title":"Chest"},{"key":"10641_CR12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/FJC.0b013e31827fe59c","volume":"61","author":"LA Morgan","year":"2013","unstructured":"Morgan, L. A. et al. Soluble epoxide hydrolase inhibition does not prevent cardiac remodeling and dysfunction after aortic constriction in rats and mice. J. Cardiovasc. Pharmacol. 61, 291\u2013301. https:\/\/doi.org\/10.1097\/FJC.0b013e31827fe59c (2013).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10641_CR13","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1093\/cvr\/cvr267","volume":"93","author":"HH Hou","year":"2012","unstructured":"Hou, H. H. et al. N-terminal domain of soluble epoxide hydrolase negatively regulates the VEGF-mediated activation of endothelial nitric oxide synthase. Cardiovasc. Res. 93, 120\u2013129. https:\/\/doi.org\/10.1093\/cvr\/cvr267 (2012).","journal-title":"Cardiovasc. Res."},{"key":"10641_CR14","doi-asserted-by":"publisher","first-page":"13524","DOI":"10.1038\/srep13524","volume":"5","author":"HH Hou","year":"2015","unstructured":"Hou, H. H., Liao, Y. J., Hsiao, S. H., Shyue, S. K. & Lee, T. S. Role of phosphatase activity of soluble epoxide hydrolase in regulating simvastatin-activated endothelial nitric oxide synthase. Sci. Rep. 5, 13524. https:\/\/doi.org\/10.1038\/srep13524 (2015).","journal-title":"Sci. Rep."},{"key":"10641_CR15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.abb.2009.05.006","volume":"489","author":"S Yang","year":"2009","unstructured":"Yang, S., Wei, S., Pozzi, A. & Capdevila, J. H. The arachidonic acid epoxygenase is a component of the signaling mechanisms responsible for VEGF-stimulated angiogenesis. Arch. Biochem. Biophys. 489, 82\u201391. https:\/\/doi.org\/10.1016\/j.abb.2009.05.006 (2009).","journal-title":"Arch. Biochem. Biophys."},{"key":"10641_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.642470","volume":"12","author":"J Lai","year":"2021","unstructured":"Lai, J. & Chen, C. The role of epoxyeicosatrienoic acids in cardiac remodeling. Front. Physiol. 12, 642470. https:\/\/doi.org\/10.3389\/fphys.2021.642470 (2021).","journal-title":"Front. Physiol."},{"key":"10641_CR17","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1161\/01.CIR.0000093190.53478.78","volume":"108","author":"T Namba","year":"2003","unstructured":"Namba, T. et al. Angiogenesis induced by endothelial nitric oxide synthase gene through vascular endothelial growth factor expression in a rat hindlimb ischemia model. Circulation 108, 2250\u20132257. https:\/\/doi.org\/10.1161\/01.CIR.0000093190.53478.78 (2003).","journal-title":"Circulation"},{"key":"10641_CR18","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/hypertensionaha.117.10271","volume":"71","author":"AK Pandey","year":"2018","unstructured":"Pandey, A. K. et al. Mechanisms of VEGF (Vascular Endothelial Growth Factor) inhibitor-associated hypertension and vascular disease. Hypertension 71, e1\u2013e8. https:\/\/doi.org\/10.1161\/hypertensionaha.117.10271 (2018).","journal-title":"Hypertension"},{"key":"10641_CR19","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1136\/heartjnl-2016-309983","volume":"102","author":"CR MacIntyre","year":"2016","unstructured":"MacIntyre, C. R., Mahimbo, A., Moa, A. M. & Barnes, M. Influenza vaccine as a coronary intervention for prevention of myocardial infarction. Heart (Br. Card. Soc.) 102, 1953\u20131956. https:\/\/doi.org\/10.1136\/heartjnl-2016-309983 (2016).","journal-title":"Heart (Br. Card. Soc.)"},{"key":"10641_CR20","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1159\/000493572","volume":"141","author":"K Fountoulaki","year":"2018","unstructured":"Fountoulaki, K., Tsiodras, S., Polyzogopoulou, E., Olympios, C. & Parissis, J. Beneficial effects of vaccination on cardiovascular events: myocardial infarction, stroke, heart failure. Cardiology 141, 98\u2013106. https:\/\/doi.org\/10.1159\/000493572 (2018).","journal-title":"Cardiology"},{"key":"10641_CR21","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.2337\/dc20-0229","volume":"43","author":"D Modin","year":"2020","unstructured":"Modin, D. et al. Influenza vaccination is associated with reduced cardiovascular mortality in adults with diabetes: A nationwide cohort study. Diabetes Care 43, 2226\u20132233. https:\/\/doi.org\/10.2337\/dc20-0229 (2020).","journal-title":"Diabetes Care"},{"issue":"3","key":"10641_CR22","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/1054-8807(95)00021-V","volume":"4","author":"CJ Cooper","year":"1995","unstructured":"Cooper, C. J., Pfeffer, J. M., Finn, P. & Pfeffer, M. A. Characteristics of a model of myocardial infarction produced by coronary artery ligation in the rat. Cardiovasc. Pathol. 4(3), 189\u2013194 (1995).","journal-title":"Cardiovasc. Pathol."},{"key":"10641_CR23","doi-asserted-by":"publisher","first-page":"11612","DOI":"10.1073\/pnas.1930406100","volume":"100","author":"C Moon","year":"2003","unstructured":"Moon, C. et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc. Natl. Acad. Sci. U.S.A. 100, 11612\u201311617. https:\/\/doi.org\/10.1073\/pnas.1930406100 (2003).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10641_CR24","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/s0076-6879(07)35008-8","volume":"435","author":"GG Camici","year":"2007","unstructured":"Camici, G. G. et al. Constitutively overexpressed erythropoietin reduces infarct size in a mouse model of permanent coronary artery ligation. Methods Enzymol. 435, 147\u2013155. https:\/\/doi.org\/10.1016\/s0076-6879(07)35008-8 (2007).","journal-title":"Methods Enzymol."},{"key":"10641_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-020-07006-9","author":"RA Eid","year":"2020","unstructured":"Eid, R. A. et al. Exendin-4 attenuates remodeling in the remote myocardium of rats after an acute myocardial infarction by activating \u03b2-arrestin-2, protein phosphatase 2A, and glycogen synthase kinase-3 and inhibiting \u03b2-catenin. Cardiovasc. Drugs Ther https:\/\/doi.org\/10.1007\/s10557-020-07006-9 (2020).","journal-title":"Cardiovasc. Drugs Ther"},{"key":"10641_CR26","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.046565","author":"C De Villiers","year":"2020","unstructured":"De Villiers, C. & Riley, P. R. Mouse models of myocardial infarction: comparing permanent ligation and ischaemia-reperfusion. Dis. Model. Mech. https:\/\/doi.org\/10.1242\/dmm.046565 (2020).","journal-title":"Dis. Model. Mech."},{"key":"10641_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060493","volume":"8","author":"F Nakagami","year":"2013","unstructured":"Nakagami, F. et al. Decrease in blood pressure and regression of cardiovascular complications by angiotensin II vaccine in mice. PLoS ONE 8, e60493. https:\/\/doi.org\/10.1371\/journal.pone.0060493 (2013).","journal-title":"PLoS ONE"},{"key":"10641_CR28","doi-asserted-by":"publisher","first-page":"43920","DOI":"10.1038\/srep43920","volume":"7","author":"R Watanabe","year":"2017","unstructured":"Watanabe, R. et al. A peptide vaccine targeting angiotensin II attenuates the cardiac dysfunction induced by myocardial infarction. Sci. Rep. 7, 43920. https:\/\/doi.org\/10.1038\/srep43920 (2017).","journal-title":"Sci. Rep."},{"key":"10641_CR29","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1038\/s41467-020-16347-w","volume":"11","author":"S Yoshida","year":"2020","unstructured":"Yoshida, S. et al. The CD153 vaccine is a senotherapeutic option for preventing the accumulation of senescent T cells in mice. Nat. Commun. 11, 2482. https:\/\/doi.org\/10.1038\/s41467-020-16347-w (2020).","journal-title":"Nat. Commun."},{"key":"10641_CR30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.yjmcc.2008.09.711","volume":"46","author":"SN Batchu","year":"2009","unstructured":"Batchu, S. N., Law, E., Brocks, D. R., Falck, J. R. & Seubert, J. M. Epoxyeicosatrienoic acid prevents postischemic electrocardiogram abnormalities in an isolated heart model. J. Mol. Cell. Cardiol. 46, 67\u201374. https:\/\/doi.org\/10.1016\/j.yjmcc.2008.09.711 (2009).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10641_CR31","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.yjmcc.2009.08.017","volume":"47","author":"N Li","year":"2009","unstructured":"Li, N. et al. Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approaches. J. Mol. Cell. Cardiol. 47, 835\u2013845. https:\/\/doi.org\/10.1016\/j.yjmcc.2009.08.017 (2009).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10641_CR32","doi-asserted-by":"publisher","first-page":"H2128","DOI":"10.1152\/ajpheart.00428.2008","volume":"295","author":"A Motoki","year":"2008","unstructured":"Motoki, A. et al. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo. Am. J. Physiol. Heart Circ. Physiol. 295, H2128-2134. https:\/\/doi.org\/10.1152\/ajpheart.00428.2008 (2008).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10641_CR33","doi-asserted-by":"publisher","first-page":"17690","DOI":"10.1002\/jcp.28395","volume":"234","author":"J Zou","year":"2019","unstructured":"Zou, J. et al. VEGF-A promotes angiogenesis after acute myocardial infarction through increasing ROS production and enhancing ER stress-mediated autophagy. J. Cell. Physiol. 234, 17690\u201317703. https:\/\/doi.org\/10.1002\/jcp.28395 (2019).","journal-title":"J. Cell. Physiol."},{"key":"10641_CR34","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1038\/s41598-019-39222-1","volume":"9","author":"T Nishikido","year":"2019","unstructured":"Nishikido, T. et al. COA-Cl (2-Cl-C.OXT-A) can promote coronary collateral development following acute myocardial infarction in mice. Sci. Rep. 9, 2533. https:\/\/doi.org\/10.1038\/s41598-019-39222-1 (2019).","journal-title":"Sci. Rep."},{"key":"10641_CR35","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/jnc.13933","volume":"140","author":"Y Zhang","year":"2017","unstructured":"Zhang, Y. et al. Inhibition of soluble epoxide hydrolase augments astrocyte release of vascular endothelial growth factor and neuronal recovery after oxygen-glucose deprivation. J. Neurochem. 140, 814\u2013825. https:\/\/doi.org\/10.1111\/jnc.13933 (2017).","journal-title":"J. Neurochem."},{"key":"10641_CR36","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1254\/jphs.08122fp","volume":"108","author":"S Suzuki","year":"2008","unstructured":"Suzuki, S., Oguro, A., Osada-Oka, M., Funae, Y. & Imaoka, S. Epoxyeicosatrienoic acids and\/or their metabolites promote hypoxic response of cells. J. Pharmacol. Sci. 108, 79\u201388. https:\/\/doi.org\/10.1254\/jphs.08122fp (2008).","journal-title":"J. Pharmacol. Sci."},{"key":"10641_CR37","doi-asserted-by":"publisher","first-page":"5294","DOI":"10.3390\/ijms21155294","volume":"21","author":"M Braile","year":"2020","unstructured":"Braile, M. et al. VEGF-A in cardiomyocytes and heart diseases. Int. J. Mol. Sci. 21, 5294. https:\/\/doi.org\/10.3390\/ijms21155294 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"10641_CR38","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.prostaglandins.2015.04.004","volume":"120","author":"L Vanella","year":"2015","unstructured":"Vanella, L. et al. Soluble epoxide hydrolase null mice exhibit female and male differences in regulation of vascular homeostasis. Prostaglandins Other Lipid Mediat. 120, 139\u2013147. https:\/\/doi.org\/10.1016\/j.prostaglandins.2015.04.004 (2015).","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10641_CR39","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1172\/JCI58128","volume":"122","author":"D Panigrahy","year":"2012","unstructured":"Panigrahy, D. et al. Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J. Clin. Invest. 122, 178\u2013191. https:\/\/doi.org\/10.1172\/JCI58128 (2012).","journal-title":"J. Clin. Invest."},{"key":"10641_CR40","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/j.1365-2362.2006.01634.x","volume":"36","author":"BT Larsen","year":"2006","unstructured":"Larsen, B. T., Gutterman, D. D. & Hatoum, O. A. Emerging role of epoxyeicosatrienoic acids in coronary vascular function. Eur. J. Clin. Invest. 36, 293\u2013300. https:\/\/doi.org\/10.1111\/j.1365-2362.2006.01634.x (2006).","journal-title":"Eur. J. Clin. Invest."},{"key":"10641_CR41","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/FJC.0b013e3181506445","volume":"50","author":"N Chiamvimonvat","year":"2007","unstructured":"Chiamvimonvat, N., Ho, C. M., Tsai, H. J. & Hammock, B. D. The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J. Cardiovasc. Pharmacol. 50, 225\u2013237. https:\/\/doi.org\/10.1097\/FJC.0b013e3181506445 (2007).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10641_CR42","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1111\/jcmm.13412","volume":"22","author":"Y Guo","year":"2018","unstructured":"Guo, Y. et al. TPPU enhanced exercise-induced epoxyeicosatrienoic acid concentrations to exert cardioprotection in mice after myocardial infarction. J. Cell. Mol. Med. 22, 1489\u20131500. https:\/\/doi.org\/10.1111\/jcmm.13412 (2018).","journal-title":"J. Cell. Mol. Med."},{"key":"10641_CR43","doi-asserted-by":"publisher","first-page":"e0213114","DOI":"10.1371\/journal.pone.0213114","volume":"14","author":"T Kitsuka","year":"2019","unstructured":"Kitsuka, T. et al. 2-Cl-C.OXT-A stimulates contraction through the suppression of phosphodiesterase activity in human induced pluripotent stem cell-derived cardiac organoids. PLoS ONE 14, e0213114. https:\/\/doi.org\/10.1371\/journal.pone.0213114 (2019).","journal-title":"PLoS ONE"}],"updated-by":[{"DOI":"10.1038\/s41598-022-12232-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10641-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10641-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10641-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T02:04:21Z","timestamp":1669341861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10641-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10641"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-10641-x","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41598-022-12232-2","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,28]]},"assertion":[{"value":"1 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-022-12232-2","URL":"https:\/\/doi.org\/10.1038\/s41598-022-12232-2","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6923"}}